HK2 and breast cancer: Many HKII inhibitors have been effective in anti-cancer therapies, such as 3-bromopyruvate (3-BP), which was found to inhibit HKII, activate the mitochondrial cell death pathway, and deplete levels of ATP [22], and it was also shown to induce apoptosis in a breast cancer cell line (MDA-MB-231) [28].